Skin Cancer Alert: Unveiling the Truth About Non-Melanoma Skin Cancer Treatment in Japan
"A deep dive into the challenges, treatment gaps, and future hopes for advanced non-melanoma skin cancer patients in Japan."
For years, melanoma has dominated the spotlight in skin cancer research and treatment, overshadowing other forms of skin cancer that, while less aggressive, still pose significant health challenges. Non-melanoma skin cancers (NMSCs), including squamous cell carcinoma (SCC), extramammary Paget's disease (EMPD), and cutaneous angiosarcoma (CAS), are increasingly prevalent, particularly in aging populations.
In Japan, a recent nationwide survey has shed light on the state of NMSC treatment, revealing critical gaps and potential paths forward. This survey, conducted across dermatology departments in Japan, highlights the challenges faced by patients with advanced NMSCs and underscores the urgent need for innovative treatment strategies.
This article dives deep into the survey's findings, exploring the current treatment landscape, the unmet needs of NMSC patients, and the promising developments on the horizon. By understanding the realities of NMSC treatment in Japan, we can advocate for better care and support for those affected by these often-overlooked cancers.
Current Burden
Skin cancer is the most common form of cancer in the United States, according to the CDC. The CDC notes that central cancer registries collect data on melanoma and nonepithelial skin cancers, including Merkel cell carcinoma, a rare but often aggressive type of skin cancer. The World Health Organization's GLOBOCAN fact sheet provides age-standardized incidence-rate data for non-melanoma skin cancer, although the supplied excerpt does not report a specific figure. A 2026 Dermatology Times report links much of skin-cancer risk to cumulative sun exposure and describes much of that risk as preventable.
Established Treatment
Non-melanoma skin cancers include basal cell carcinoma and cutaneous squamous cell carcinoma, which account for the vast majority of global skin-cancer diagnoses. The NCI lists surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy among treatment options for nonmelanoma skin cancers. Treatment choice depends on the cell type and extent of disease. Although mortality is low, tumor burden can still cause significant morbidity through local compression and invasion.
The Reality of Advanced NMSC in Japan: Key Findings
The survey, which reached 668 certified dermatology training facilities across Japan, paints a concerning picture. Researchers found that the number of patients with advanced NMSCs is significant, with an estimated 1255.6 cases annually. This figure underscores the prevalence of these cancers and the substantial burden they place on the healthcare system.
- Prevalence: Squamous cell carcinoma (SCC) is the most common NMSC, followed by extramammary Paget's disease (EMPD), other skin carcinomas, and cutaneous angiosarcoma (CAS).
- Limited Treatment Options: Current treatments for advanced NMSCs primarily involve chemotherapy, which often has significant side effects and limited effectiveness.
- Uneven Distribution of Care: Advanced NMSC cases are concentrated in university hospitals and cancer centers, suggesting that patients in rural areas may face challenges accessing specialized care.
- Need for New Drugs: There's a clear consensus among dermatologists that new and more effective treatments are desperately needed for advanced NMSCs.
Japanese Evidence
Japan's National Cancer Registry data for 2016–2017 reported squamous cell carcinoma as 43.9% of recorded skin-cancer subtypes, with 18.3% of those cases in situ, and basal cell carcinoma as 37.2%. The same analysis reported malignant melanoma at 7.2%, extramammary Paget's disease at 3.1%, adnexal carcinoma at 2.9%, dermatofibrosarcoma protuberans at 0.9%, Merkel cell carcinoma at 0.6%, angiosarcoma at 0.5%, and hematologic malignancies at 3.8%. Separately, the Japanese Melanoma Study analyzed data from 7,442 Japanese melanoma patients collected between 2005 and 2022. A cited Japanese nationwide survey addressed advanced non-melanoma skin cancers treated in dermatology departments.
Treatment Choices
Non-melanoma skin-cancer treatment offers options ranging from non-invasive approaches to surgery. Kaiser Permanente notes that each option has advantages and disadvantages and that a doctor recommends the best treatment for the individual patient. The supplied Dermatology Advisor material describes an analysis of 2,917 invasive and in situ keratinocytic carcinoma lesions treated with image-guided superficial radiation therapy. Sensus Healthcare presents superficial radiotherapy as a non-invasive alternative emphasizing efficacy and cosmetic outcomes, particularly for patients seeking an alternative to surgery.
Looking Ahead: Promising Developments and Future Directions
Despite the challenges, there's reason for hope. The survey revealed that dermatologists in Japan are optimistic about the potential of new treatments, particularly EGFR inhibitors and immune checkpoint inhibitors, which have shown promise in treating other cancers, including head and neck SCC. For EMPD, researchers are exploring the potential of HER2 inhibitors, while for CAS, immune checkpoint inhibitors are generating excitement.
Evidence-Based Decisions
Consensus work on cutaneous squamous cell carcinoma treatment reviews medical literature across multiple treatment methods. The review considers cure rates, recurrence and metastatic rates, aesthetic and functional outcomes, and cost effectiveness. The supplied expert-interview material identifies Prof Hauschild's clinical interests as the diagnosis and treatment of melanoma and nonmelanoma skin cancer. It also reports that he has been the principal investigator of more than 100 Phase I–III clinical trials involving melanoma, cutaneous lymphomas, and epithelial skin cancers.
Market and Innovation
Market projections for non-melanoma skin-cancer treatment differ across the supplied reports. Research and Markets values the market at US$620 million in 2026 and projects a 3.9% compound annual growth rate to reach US$805 million by 2034. IMARC estimates the global market at US$614.2 million in 2025 and projects US$881.5 million by 2034, at a 4.10% compound annual growth rate during 2026–2034. The Skin Cancer Foundation's 2025 progress report highlights more treatment options for advanced squamous cell carcinoma and basal cell carcinoma.